Spyre Therapeutics (SYRE) Short term Debt (2023 - 2026)

Spyre Therapeutics (SYRE) has 4 years of Short term Debt data on file, last reported at $50.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 17.4% year-over-year to $50.3 million; the trailing twelve-month figure through Mar 2026 stood at $50.3 million (up 17.4% YoY), and the FY2025 full-year result was $22.8 million, down 9.01% from the prior year.
• Short term Debt for Q1 2026 stood at $50.3 million, up from $22.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $164.4 million in Q2 2023 and bottomed at $1.4 million in Q4 2023.
• The 4-year median for Short term Debt is $23.8 million (2024), against an average of $34.6 million.
• The widest annual swing landed in 2024, when Short term Debt slumped 98.39%; it then jumped 2168.94% in 2025.
• A 4-year view of Short term Debt shows it stood at $1.4 million in 2023, then jumped by 1704.32% to $25.1 million in 2024, then dropped by 9.01% to $22.8 million in 2025, then soared by 120.25% to $50.3 million in 2026.
• The last three Short term Debt figures came in at $50.3 million (Q1 2026), $22.8 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.

Peer Comparison